Raees Tonse, Radiation Oncologist, Founder/CEO of NAZR Venture, Global Advocate for Preventative Healthcare and Longevity, shared a post by NAZR Ventures, on LinkedIn, adding:
“This initiative is deeply personal to me. Having worked closely with proton therapy over the years, I’ve seen firsthand its clinical potential – and also the structural barriers that have limited broader adoption.
Through NAZR Ventures, we are focused on building scalable, capital-aligned frameworks that can responsibly expand access to advanced proton therapy oncology infrastructure across global markets. More to come as this work progresses. For strategic discussions or partnership enquiries, please contact.”
Quoting NAZR Ventures post:
“NAZR Ventures is advancing its focus on the scaling of next-generation proton therapy oncology infrastructure through structured, capital-efficient deployment models.
Our approach centers on:
- Platform-based scaling of clinically differentiated technologies.
- Financing and capital frameworks aligned with long-life healthcare infrastructure.
- Partnerships with hospitals, health systems, and institutional capital providers.
- Deployment in markets with strong clinical demand and sustainable economics.
Proton therapy represents a critical component of the future oncology landscape, yet its adoption has been constrained by traditional capital and execution models. NAZR Ventures is working to bridge technology, capital, and healthcare systems to enable responsible, scalable access to advanced cancer care.
More to follow as we progress these initiatives across select global markets.”
More posts featuring Proton Therapy on OncoDaily.
